Botanix Pharmaceuticals Dividend

Dividend criteria checks 0/6

Botanix Pharmaceuticals does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.3%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-AU$0.0064
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

Mar 21

Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Sep 06

Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Jan 03

Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Sep 05

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

May 10

The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More

Jan 24

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

Nov 30

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if BOT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BOT's dividend payments have been increasing.

Dividend Yield vs Market

Botanix Pharmaceuticals Dividend Yield vs Market

How does BOT dividend yield compare to the market?
Segment	Dividend Yield
Company (BOT)	n/a
Market Bottom 25% (AU)	2.6%
Market Top 25% (AU)	6.2%
Industry Average (Pharmaceuticals)	2.3%
Analyst forecast in 3 Years (BOT)	n/a

Notable Dividend: Unable to evaluate BOT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BOT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate BOT's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BOT has not reported any payouts.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Botanix Pharmaceuticals Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

New minor risk - Financial position

Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024

Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.

Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.

Full year 2023 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2022)

Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive Officer

Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023

New minor risk - Share price stability

Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Botanix Pharmaceuticals Limited Announces Confirmation Sofpironium Bromide Nda Formally Under Review

Less than half of directors are independent

Botanix Pharmaceuticals Limited Promotes Howie Mckibbon to Chief Operating Officer

Botanix Pharmaceuticals Limited Announces Positive Data from its BTX 1702 Phase 1B/2 Papulopustular Rosacea Clinical Study

Botanix Pharmaceuticals Limited Submits FDA New Drug Application for Sofpironium Bromide

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 03, 2022

Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.003 loss in FY 2021)

MD, President & Executive Chairman exercised options to buy AU$370k worth of stock.

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Less than half of directors are independent

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Commercial Officer and Patricia Walker as Chief Medical Adviser

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

We're Not Very Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate

Botanix Pharmaceuticals Limited Announces Launch of Canine Atopic Dermatitis Program

Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.018 loss in FY 2020)

We Think Botanix Pharmaceuticals (ASX:BOT) Can Afford To Drive Business Growth

Botanix Pharmaceuticals Limited Announces Results from BTX 1204A Pilot Study

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

First half 2021 earnings released: EPS AU$0.001 (vs AU$0.008 loss in 1H 2020)

Botanix Pharmaceuticals Limited Expands Management Team

Botanix Pharmaceuticals Limited Announces Positive Top-Line Data from BTX 1801 Phase 2A Nasal Decolonisation Proof of Concept Study

The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More

Botanix Pharmaceuticals Limited Publishes Antimicrobial Data in Peer-Reviewed Research Journal

Botanix Pharmaceuticals Limited Provides Update on BTX 1801 Phase 2A Clinical Study

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

Botanix Pharmaceuticals Limited(ASX:BOT) dropped from S&P/ASX Emerging Companies Index

Full year earnings released - AU$0.018 loss per share

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies